DexCom (Germany) Performance
| DC4 Stock | EUR 73.54 0.92 1.24% |
On a scale of 0 to 100, DexCom holds a performance score of 9. The firm shows a Beta (market volatility) of 0.071, which means not very significant fluctuations relative to the market. As returns on the market increase, DexCom's returns are expected to increase less than the market. However, during the bear market, the loss of holding DexCom is expected to be smaller as well. Please check DexCom's value at risk, downside variance, and the relationship between the maximum drawdown and potential upside , to make a quick decision on whether DexCom's price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in DexCom Inc are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, DexCom reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.1 B |
DexCom |
DexCom Relative Risk vs. Return Landscape
If you would invest 6,438 in DexCom Inc on August 29, 2024 and sell it today you would earn a total of 1,008 from holding DexCom Inc or generate 15.66% return on investment over 90 days. DexCom Inc is currently producing 0.2464% returns and takes up 2.1477% volatility of returns over 90 trading days. Put another way, 19% of traded stocks are less volatile than DexCom, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
DexCom Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DexCom's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DexCom Inc, and traders can use it to determine the average amount a DexCom's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1147
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DC4 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.15 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 9 91% of assets perform better |
Based on monthly moving average DexCom is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DexCom by adding it to a well-diversified portfolio.
DexCom Fundamentals Growth
DexCom Stock prices reflect investors' perceptions of the future prospects and financial health of DexCom, and DexCom fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DexCom Stock performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0474 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 42.38 B | |||
| Shares Outstanding | 386.41 M | |||
| Price To Earning | 191.84 X | |||
| Price To Book | 24.95 X | |||
| Price To Sales | 15.73 X | |||
| Revenue | 2.91 B | |||
| EBITDA | 565.3 M | |||
| Cash And Equivalents | 1.38 B | |||
| Cash Per Share | 15.11 X | |||
| Total Debt | 1.2 B | |||
| Debt To Equity | 159.90 % | |||
| Book Value Per Share | 5.52 X | |||
| Cash Flow From Operations | 669.5 M | |||
| Earnings Per Share | 0.75 X | |||
| Total Asset | 5.39 B | |||
About DexCom Performance
By analyzing DexCom's fundamental ratios, stakeholders can gain valuable insights into DexCom's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DexCom has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DexCom has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DEXCOM INC operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2800 people.Things to note about DexCom Inc performance evaluation
Checking the ongoing alerts about DexCom for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DexCom Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DexCom Inc has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Over 100.0% of the company shares are held by institutions such as insurance companies |
- Analyzing DexCom's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DexCom's stock is overvalued or undervalued compared to its peers.
- Examining DexCom's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DexCom's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DexCom's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DexCom's stock. These opinions can provide insight into DexCom's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |